IDEAYA Biosciences Reports Strong Q1 Financial Results and Advances in Oncology Drug Development

May 6, 2025 — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused biotechnology company, has announced its first quarter 2025 financial results, showcasing a robust financial position and significant progress in its drug development pipeline. As of March 31, 2025, the company reported having approximately $1.05 billion in cash, cash equivalents, and marketable securities. This strong financial standing extends the company’s cash runway guidance into 2029, underscoring its commitment to advancing its oncology therapeutics.

In its ongoing efforts to combat cancer, IDEAYA Biosciences has made notable strides in its clinical trials. The company has successfully enrolled over 300 patients in a registrational trial for darovasertib and crizotinib, targeting HLA-A2-negative MUM. The trial aims to achieve median progression-free survival (PFS) results by the end of 2025, which could potentially support an accelerated approval filing.

Additionally, IDEAYA Biosciences completed a successful FDA Type D meeting to finalize the design of the Phase 3 registrational trial for darovasertib. The company also received Breakthrough Therapy Designation from the U.S. FDA for neoadjuvant UM, further highlighting the potential of darovasertib in oncology treatment.

In another significant development, IDEAYA Biosciences announced the U.S. FDA IND-clearance for IDE849, a potential first-in-class DLL3 TOP1 antibody-drug conjugate (ADC), for a Phase 1 study in solid tumors. The company plans to evaluate IDE849 in small cell lung cancer (SCLC), neuroendocrine tumors (NETs), and other DLL3-upregulated solid tumors. Additionally, IDEAYA aims to explore the combination of IDE849 with IDE161/PARG to potentially enhance treatment durability. Clinical data from over 40 SCLC patients, including dose escalation and expansion, is expected to be presented at a medical conference in Q3 2025.

Despite these advancements, IDEAYA Biosciences reported a GAAP earnings per share (EPS) of -$0.82 for the quarter, missing estimates by $0.15. This financial performance reflects the company’s ongoing investment in its research and development efforts.

Analysts have highlighted IDEAYA Biosciences as one of the best small-cap stocks to buy, citing its significant upside potential. The company’s strategic focus on developing targeted therapeutics and its strong financial position position it well for future growth in the oncology sector.

Overall, IDEAYA Biosciences continues to demonstrate its commitment to advancing innovative cancer treatments, supported by a solid financial foundation and promising clinical developments.